Physician profile
Justo Sataray
NPI 1689619983
$7,229.22
in general payments reported to CMS, 2019-2025
33 companies · $1,436 in 2025
The $1,436 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,435 · 2020: $1,021 · 2021: $1,154 · 2022: $756 · 2023: $458 · 2024: $969 · 2025: $1,436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,820 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,820.44 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,460.74 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,162.68 | 2019-2025 | Xifaxan |
| Novo Nordisk INC | $530.62 | 2019-2025 | Rybelsus, Ozempic, Tresiba |
| Abbott Laboratories | $528.27 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $501.35 | 2019-2025 | |
| Abbvie INC. | $427.15 | 2021-2025 | Vraylar |
| Allergan, INC. | $400.69 | 2019-2020 | |
| Lilly USA, LLC | $289.49 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Novartis Pharmaceuticals Corporation | $252.09 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $207.78 | 2019-2021 | |
| W. L. Gore & Associates, INC. | $175.00 | 2025 | Excluder Conformable Aaa Endoprosthesis With Active Control |
| Amgen INC. | $169.04 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $145.75 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.31 | 2019-2022 | |
| Astellas Pharma US INC | $96.58 | 2023-2025 | Veozah |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $96.47 | 2019-2021 | |
| Boston Scientific Corporation | $95.56 | 2021 | |
| Mannkind Corporation | $87.98 | 2019-2025 | |
| Dexcom, INC. | $79.16 | 2022-2025 | Dexcom G6 Transmitter |
| Hologic Sales and Service, LLC | $65.44 | 2021-2025 | Aptima, Thinprep 2000 Processor |
| Genentech USA, INC. | $53.67 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.82 | 2025 | |
| Redhill Biopharma INC. | $33.43 | 2021-2022 | |
| Exact Sciences Corporation | $33.42 | 2023 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $30.40 | 2021 | |
| Horizon Therapeutics Plc | $25.92 | 2021-2022 | |
| Corcept Therapeutics | $24.86 | 2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $21.68 | 2019 | |
| Phathom Pharmaceuticals, INC. | $21.04 | 2025 | Voquezna |
| Lundbeck LLC | $17.32 | 2023 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $15.70 | 2022 | |
| Radius Health, INC. | $15.63 | 2020 | |
| Vertiflex, INC. | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justo Sataray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.